Advertisement
Advertisement
REGN
Regeneron Pharmaceuticals Inc
713.33
USDSponsored
-7.72
-1.07%
May 07, 13:47 UTC -4
Open
REGN Earnings Reports
Positive Surprise Ratio
REGN beat 34 of 41 last estimates.
83%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.90B
/$11.13
Implied change from Q1 26 (Revenue/ EPS)
+8.20%
/+17.53%
Implied change from Q2 25 (Revenue/ EPS)
+6.13%
/-13.65%
Regeneron Pharmaceuticals Inc earnings per share and revenue
On Apr 29, 2026, REGN reported earnings of 9.47 USD per share (EPS) for Q1 26, beating the estimate of 9.11 USD, resulting in a 3.88% surprise. Revenue reached 3.61 billion, compared to an expected 3.56 billion, with a 1.38% difference. The market reacted with a -6.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of 11.13 USD, with revenue projected to reach 3.90 billion USD, implying an increase of 17.53% EPS, and increase of 8.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Insmed, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.98
Actual
-$0.76
Surprise
+22.83%
Praxis Precision Medicines, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$3.64
Actual
-$3.20
Surprise
+12.09%
Nuvalent, Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.34
Actual
-$1.39
Surprise
-3.41%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
Ligand Pharmaceuticals Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.85
Actual
$1.63
Surprise
-11.99%
Edgewise Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.46
Surprise
+7.33%
Palvella Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.95
Actual
-$1.20
Surprise
-26.21%
Rapport Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.68
Actual
-$0.42
Surprise
+38.61%
Lexicon Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.03
Actual
$0.00
Surprise
+100.00%
FAQ
What were Regeneron Pharmaceuticals Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Regeneron Pharmaceuticals Inc reported EPS of $9.47, beating estimates by 3.88%, and revenue of $3.61B, 1.38% above expectations.
How did the market react to Regeneron Pharmaceuticals Inc's Q1 2026 earnings?
The stock price moved down -6.21%, changed from $731.77 before the earnings release to $686.36 the day after.
When is Regeneron Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for Regeneron Pharmaceuticals Inc's next earnings report?
Based on 11
analysts, Regeneron Pharmaceuticals Inc is expected to report EPS of $11.13 and revenue of $3.90B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement